Brokerage firm Jefferies Maintains its rating on Insys Therapeutics Inc(NASDAQ:INSY). In a research note issued to the investors, the brokerage major Lowers the price-target to $17.00 per share. The shares have been rated Buy. The rating by Jefferies was issued on Apr 12, 2016.
In a different note, On Mar 9, 2016, JMP Securities said it Maintains its rating on Insys Therapeutics Inc. In the research note, the firm Lowers the price-target to $38.00 per share. The shares have been rated ‘Market Outperform’ by the firm. On Feb 24, 2016, Jefferies said it Maintains its rating on Insys Therapeutics Inc. In the research note, the firm Lowers the price-target to $36.00 per share. The shares have been rated ‘Buy’ by the firm.
Insys Therapeutics Inc (INSY) shares turned negative on Fridays trading session with the shares closing down -0.07 points or -0.49% at a volume of 3,03,351. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $14.4864. The peak price level was also seen at $14.4864 while the days lowest was $14. Finally the shares closed at $14.32. The 52-week high of the shares is $46.17 while the 52-week low is $12.5. According to the latest information available, the market cap of the company is $1,024 M.
Insys Therapeutics Inc(INSY) last announced its earnings results on Feb 23, 2016 for Fiscal Year 2015 and Q4.Company reported revenue of $91.14M. Analysts had an estimated revenue of $91.04M. Earnings per share were $0.36. Analysts had estimated an EPS of $0.29.
Several Insider Transactions has been reported to the SEC. On Mar 7, 2016, Patrick Fourteau (director) sold 15,000 shares at $18.22 per share price.Also, On Mar 4, 2016, Theodore H Stanley (director) sold 20,000 shares at $18.11 per share price.On Nov 18, 2015, John N Kapoor (CEO) purchased 5,000 shares at $29.77 per share price, according to the Form-4 filing with the securities and exchange commission.
Insys Therapeutics Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company has two marketed products: Subsys a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and Dronabinol SG Capsule a generic equivalent to Marinol (dronabinol) an approved second-line treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS. The Companys lead product candidate is Dronabinol oral solution an orally administered liquid formulation of dronabinol. Dronabinol oral solution has demonstrated more rapidly detectable blood levels and a more reliable absorption profile than Marinol in its clinical studies.